229 related articles for article (PubMed ID: 19622769)
1. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.
Yang E; Boire A; Agarwal A; Nguyen N; O'Callaghan K; Tu P; Kuliopulos A; Covic L
Cancer Res; 2009 Aug; 69(15):6223-31. PubMed ID: 19622769
[TBL] [Abstract][Full Text] [Related]
2. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer.
Cisowski J; O'Callaghan K; Kuliopulos A; Yang J; Nguyen N; Deng Q; Yang E; Fogel M; Tressel S; Foley C; Agarwal A; Hunt SW; McMurry T; Brinckerhoff L; Covic L
Am J Pathol; 2011 Jul; 179(1):513-23. PubMed ID: 21703428
[TBL] [Abstract][Full Text] [Related]
3. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.
Agarwal A; Covic L; Sevigny LM; Kaneider NC; Lazarides K; Azabdaftari G; Sharifi S; Kuliopulos A
Mol Cancer Ther; 2008 Sep; 7(9):2746-57. PubMed ID: 18790755
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting of breast and colon cancer cells by PAR1 mediated apoptosis through a novel pro-apoptotic peptide.
Ray T; Kar D; Pal A; Mukherjee S; Das C; Pal A
Apoptosis; 2018 Dec; 23(11-12):679-694. PubMed ID: 30196356
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.
Rahman KM; Ali S; Aboukameel A; Sarkar SH; Wang Z; Philip PA; Sakr WA; Raz A
Mol Cancer Ther; 2007 Oct; 6(10):2757-65. PubMed ID: 17913854
[TBL] [Abstract][Full Text] [Related]
6. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.
Boire A; Covic L; Agarwal A; Jacques S; Sherifi S; Kuliopulos A
Cell; 2005 Feb; 120(3):303-13. PubMed ID: 15707890
[TBL] [Abstract][Full Text] [Related]
7. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.
Agarwal A; Tressel SL; Kaimal R; Balla M; Lam FH; Covic L; Kuliopulos A
Cancer Res; 2010 Jul; 70(14):5880-90. PubMed ID: 20570895
[TBL] [Abstract][Full Text] [Related]
8. Distinct activity of peptide mimetic intracellular ligands (pepducins) for proteinase-activated receptor-1 in multiple cells/tissues.
Kubo S; Ishiki T; Doe I; Sekiguchi F; Nishikawa H; Kawai K; Matsui H; Kawabata A
Ann N Y Acad Sci; 2006 Dec; 1091():445-59. PubMed ID: 17341635
[TBL] [Abstract][Full Text] [Related]
9. Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.
Adams LS; Phung S; Yee N; Seeram NP; Li L; Chen S
Cancer Res; 2010 May; 70(9):3594-605. PubMed ID: 20388778
[TBL] [Abstract][Full Text] [Related]
10. Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach.
Covic L; Kuliopulos A
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065181
[TBL] [Abstract][Full Text] [Related]
11. Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
Zhu Y; Tao Z; Chen Y; Lin S; Zhu M; Ji W; Liu X; Li T; Hu X
Breast Cancer Res Treat; 2022 May; 193(1):65-81. PubMed ID: 35254603
[TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibition of migration and invasion of breast cancer cells by dual docetaxel/quercetin-loaded nanoparticles via Akt/MMP-9 pathway.
Li J; Zhang J; Wang Y; Liang X; Wusiman Z; Yin Y; Shen Q
Int J Pharm; 2017 May; 523(1):300-309. PubMed ID: 28336457
[TBL] [Abstract][Full Text] [Related]
13. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
McAuley JR; Bailey KM; Ekambaram P; Klei LR; Kang H; Hu D; Freeman TJ; Concel VJ; Hubel NE; Lee JL; Klei HB; Cheng J; Sekar P; Bridwell RE; Covic L; Lucas PC; McAllister-Lucas LM
Oncogene; 2019 Dec; 38(49):7384-7398. PubMed ID: 31420608
[TBL] [Abstract][Full Text] [Related]
14. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Rana R; Huang T; Koukos G; Fletcher EK; Turner SE; Shearer A; Gurbel PA; Rade JJ; Kimmelstiel CD; Bliden KP; Covic L; Kuliopulos A
Arterioscler Thromb Vasc Biol; 2018 Jun; 38(6):1368-1380. PubMed ID: 29622563
[TBL] [Abstract][Full Text] [Related]
15. MPPa-PDT suppresses breast tumor migration/invasion by inhibiting Akt-NF-κB-dependent MMP-9 expression via ROS.
Huang L; Lin H; Chen Q; Yu L; Bai D
BMC Cancer; 2019 Nov; 19(1):1159. PubMed ID: 31783821
[TBL] [Abstract][Full Text] [Related]
16. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways.
Zhou R; Xu L; Ye M; Liao M; Du H; Chen H
Horm Metab Res; 2014 Oct; 46(11):753-60. PubMed ID: 24977660
[TBL] [Abstract][Full Text] [Related]
17. Ulinastatin exerts synergistic effects with taxotere and inhibits invasion and metastasis of breast cancer by blocking angiogenesis and the epithelial-mesenchymal transition.
Gao F; Sun Z; Sun X; Zhang Y; Wang H; Zhong B; Luo J; Zhao X
Cancer Biother Radiopharm; 2013 Apr; 28(3):218-25. PubMed ID: 23477357
[TBL] [Abstract][Full Text] [Related]
18. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.
Kalra J; Warburton C; Fang K; Edwards L; Daynard T; Waterhouse D; Dragowska W; Sutherland BW; Dedhar S; Gelmon K; Bally M
Breast Cancer Res; 2009; 11(3):R25. PubMed ID: 19409087
[TBL] [Abstract][Full Text] [Related]
19. ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway.
Deng R; Tang J; Xia LP; Li DD; Zhou WJ; Wang LL; Feng GK; Zeng YX; Gao YH; Zhu XF
Mol Cancer Ther; 2009 Apr; 8(4):873-82. PubMed ID: 19372560
[TBL] [Abstract][Full Text] [Related]
20. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
